Jinhai Medical Technology (HKSE:02225) Notes Receivable: HK$0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02225 Jinhai Medical Technology Ltd HKSE:02225
61 GF Score
Price HK$6.05
GF Value HK$1.41
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Jinhai Medical Technology Notes Receivable?

Jinhai Medical Technology HKSE:02225 -7.14% 61 Notes Receivable is HK$0.0 Mil as of Dec. 2025. GuruFocus rates HKSE:02225 with a GF Score™ of 61/100 and a GF Value™ of HK$1.41 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Jinhai Medical Technology's Notes Receivable for the quarter that ended in Dec. 2025 was HK$0.0 Mil.


Jinhai Medical Technology Notes Receivable Related Terms


Jinhai Medical Technology Notes Receivable Historical Data

* Premium members only.

The historical data trend for Jinhai Medical Technology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jinhai Medical Technology Notes Receivable Chart

Jinhai Medical Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Jinhai Medical Technology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:02225
61GF Score
Jinhai Medical Technology Ltd HKSE:02225
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jinhai Medical Technology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0.0 Mil mean?
Jinhai Medical Technology (HKSE:02225) has a Notes Receivable of HK$0.0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Jinhai Medical Technology and its competitors.
Is Jinhai Medical Technology's Notes Receivable too high?
Jinhai Medical Technology's current Notes Receivable is HK$0.0 Mil. Overall, Jinhai Medical Technology has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinhai Medical Technology's Notes Receivable compare to RHI and KFY?
Jinhai Medical Technology's Notes Receivable of HK$0.0 Mil can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Conglomerates company?
A good Notes Receivable depends on the Conglomerates industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Jinhai Medical Technology and its competitors. Jinhai Medical Technology's current Notes Receivable is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinhai Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Jinhai Medical Technology (HKSE:02225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.41, compared to a current price of HK$6.05 — trading 328.7% above its estimated fair value. The current Notes Receivable is HK$0.0 Mil. Jinhai Medical Technology's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Jinhai Medical Technology (HKSE:02225), the current Notes Receivable is HK$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jinhai Medical Technology (HKSE:02225) Overvalued in 2026?

Based on GuruFocus' analysis, Jinhai Medical Technology stock appears to be overvalued. The current stock price of HK$6.05 is trading 328.7% above its estimated GF Value™ of HK$1.41. GuruFocus considers Jinhai Medical Technology to be Significantly Overvalued.

Key valuation signals for HKSE:02225:

  • Notes Receivable: HK$0.0 Mil
  • GF Value™: HK$1.41 vs. price of HK$6.05 (328.7% above fair value)
  • GF Score™: 61/100 with 9 warning signs

No single metric tells the full story. See the HKSE:02225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jinhai Medical Technology Business Description

Address 1275 Meichuan Road, 3rd Floor, Block East, Putuo District, Shanghai, CHN
Jinhai Medical Technology Ltd is an investment holding company. Along with its subsidiaries, it is principally engaged in providing medical equipment in China and manpower outsourcing and ancillary services to building and construction contractors in Singapore. The group also provides IT services, construction ancillary services (which comprise warehousing, cleaning, and building maintenance works), and dormitory services in Singapore. It generates maximum revenue from the sale of minimally invasive surgery solutions, medical products, and related services in the People's Republic of China.
61GF Score

Get the complete analysis for HKSE:02225

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.05
Price
HK$1.41
GF Value